Breast cancer: occurrence, risk factors and hormone metabolism

References

• Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2(9), 533–543 (2001).
   Google Scholar
• ••Overview of the burden of cancer in termsof incidence, mortality and prevalence, by type of cancer and population group. Data for the year 2000 indicate notable differences across populations, suggesting different lifestyles and environmental factors play a major role in the occurrence of cancer.
   Google Scholar
• Ferlay J, Bray I, Pisani P, Parkin DM. Globocan 2000 (CD-ROM). Cancer incidence, mortality and pmvalence worldwide. IARC Press, Lyon, France (2001).
   Google Scholar
• Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (Eds). Breast cancer. In: Cancer incidence in five continents, volume VII International Agency for Research on Cancer, Lyon, France, 858–859 (1997).
   Google Scholar
• Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int.j Cancer 41 (2), 184–197 (1988).
   Google Scholar
• Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int.j Cancer 54(4), 594–606 (1993).
   Google Scholar
• Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int.j Cancer 80(6), 827–841 (1999).
   Google Scholar
• Waterhouse J, Muir CS, Shanmugaratnam K, Powell J (Eds). Breast cancer. In: Cancer incidence in five continents, volume IV International Agency for Research on Cancer, Lyon, France, 734–735 (1982).
   Google Scholar
• Lacey JV Jr, Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Environ. Mal Mutagen 39(2–3), 82–88 (2002).
   Google Scholar
• •Interesting paper demonstrating that in young women, incidence rates are decreasing in the USA, in contrast to the situation in many other countries of the world.
   Google Scholar
• Peto R, Boreham J, Clarke M, Davies C, Beral V UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet 355(9217), 1822 (2000).
   Google Scholar
• Ménégoz F, Chérié-Challine L. Cancer du sein. In: Le cancer en France: incidence et mortalité. Situation en 1995 Evolution entre 1975 et 1995 La documentation frangaise, Paris, France, 76–81 (1998).
   Google Scholar
• Berrino F, Sant M, Verdecchia A etal (Eds). Breast. In: Survival of cancer patients in Europe. The Eumcare study IARC Scientific Publication No 132. International Agency for Research on Cancer, Lyon, France, 253–265 (1995).
   Google Scholar
• Berrino F, Capocaccia R, Esteve J etal (Eds). Breast. In: Survival of cancer patients in Europe: the Eurocarr-2 study IARC Scientific Publication No 151. International Agency for Research on Cancer, Lyon, France, 304–313 (1999).
   Google Scholar
• Sasco AJ. Epidemiology of breast cancer: an environmental disease? APIVff S109(5), 321–332 (2001).
   Google Scholar
• Russo J, Hu YF, Tahin Q etal Carcinogenicity of estrogens in human breast epithelial cells. APMIS109(1), 39–52 (2001).
   PubMedGoogle Scholar
• Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J. Mammary Gland Biol. Neoplasia 3(1), 49–61 (1998).
   Google Scholar
• •Overview of the developmental sequence that influences breast cancer susceptibility, including the role of breast differentiation in particular during pregnancy.
   Google Scholar
• Russo J, Lareef H, Tahin Q, Russo IH. Pathways of carcinogenesis and prevention in the human breast. Eur. J. Cancer 38\(Suppl. 6) S31-S32 (2002).
   Google Scholar
• Lane-Claypon JE. A further report on cancer of the breast. Reports on Public Health and Medical Subjects No. 32. His Majesty's Stationery Office, London (1926).
   Google Scholar
• Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 15(1), 36–47 (1993).
   PubMed Web of Science ®Google Scholar
• Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet 017C0i 2(3), 133–140 (2001).
   Google Scholar
• Key TJ, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur. J. Cancer Clin. Oncol 24(1), 29–43 (1988).
   Google Scholar
• Clavel-Chapelon F. Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. BE J. Cancer86(5), 723–727 (2002).
   Google Scholar
• Tung HT, Tsukuma H, Tanaka H etal Risk factors for breast cancer in Japan, with special attention to anthropometric measurements and reproductive history. Jpn. I Clin. Oncol 29(3), 137–146 (1999).
   Google Scholar
• Gao YT, Shu XO, Dai Q et al Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int.j Cancer 87(2), 295–300 (2000).
   Google Scholar
• ••
   Google Scholar
• Ssali JC, Gakwaya A, Katongole-Mbidde E Risk factors for breast cancer in Ugandan women: a case-control study. Fast Central Afr. I Surg. 1,9–13 (1995).
   Google Scholar
• Wohlfahrt J, Melbye M. Age at any birth is associated with breast cancer risk. Epidemiology12(1), 68–73 (2001).
   PubMedGoogle Scholar
• Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Arn. I Epidemiol 139(8), 819–835 (1994).
   Google Scholar
• Sanderson M, Shu XO, Jin F etal Abortion history and breast cancer risk: results from the Shanghai Breast Cancer Study. Int.j Cancer 92 (6), 899–905 (2001).
   Google Scholar
• Ye Z, Gao DL, Qin Q, Ray RM, Thomas DB. Breast cancer in relation to induced abortions in a cohort of Chinese women. Br.Cancer 87(9), 977–981 (2002).
   Google Scholar
• Lipworth L, Bailey LR, Trichopoulos D. History of breast-feeding in relation to breast cancer risk: a review of the epidemiologic literature. j Natl Cancer Inst. 92(4), 302–312 (2000).
   PubMedGoogle Scholar
• Chang-Claude J, Eby N, Kiechle M, Bastert G, Becher H. Breastfeeding and breast cancer risk by age 50 among women in Germany. Cancer Causes Control 11(8), 687–695 (2000).
   Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet 360(9328), 187–195 (2002).
   Google Scholar
• Zheng T, Holford TR, Mayne ST et al Lactation and breast cancer risk: a case-control study in Connecticut. BE j Cancer 84(11), 1472–1476 (2001).
   Google Scholar
• Tryggvadottir L, Tulinius H, Eyfjord JE, Sigurvinsson T Breast cancer risk factors and age at diagnosis: an Icelandic cohort study. Int. J. Cancer 98(4), 604–608 (2002).
   Google Scholar
• •Report of a large cohort study in Iceland demonstrating that the importance of many breast cancer risk factors depends, sometimes strongly, upon age at diagnosis.
   Google Scholar
• Clavel-Chapelon F, Gerber M. Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? Breast Cancer Res. Brat. 72(2), 107–115 (2002).
   Google Scholar
• Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 360(9336), 861–868 (2002).
   PubMed Web of Science ®Google Scholar
• World Cancer Research Fund. American Institute for Cancer Research. Food, nutrition and the prevention of cancer:. a global perspective. American Institute for Cancer Research, Washington DC, USA (1997).
   Google Scholar
• Hunter DJ, Willett WC. Nutrition and breast cancer. Cancer Causes Control 7(1), 56–68 (1996).
   PubMed Web of Science ®Google Scholar
• Smith-Warner SA, Spiegelman D, Adami HO etal Types of dietary fat and breast cancer: a pooled analysis of cohort studies. Int.j Cancer 92 (5), 767–774 (2001) .
   PubMed Web of Science ®Google Scholar
• Velie E, Kulldorff M, Schairer C etal Dietary fat, fat subtypes and breast cancer in postmenopausal women: a prospective cohort study. J. Natl Cancer Inst. 92(10), 833–839 (2000).
   PubMedGoogle Scholar
• Willett WC. Diet and cancer: one view at the start of the millennium. Cancer Epidemiol Biomarker s Pmv. 10(1), 3–8 (2001).
   Google Scholar
• Zheng W, Gustafson DR, Sinha R et al Well-done meat intake and the risk of breast cancer. J. Natl Cancer Inst. 90(22), 1724–1729 (1998).
   PubMedGoogle Scholar
• International Agency for Research on Cancer. IARC handbooks of cancer prevention, handbook 6. Wight control and physical activity International Agency for Research on Cancer, Lyon, France (2002).
   Google Scholar
• ••Comprehensive review and evaluation onthe effect of weight and physical activity on breast cancer risk, with references of all studies published up to 2000.
   Google Scholar
• Berkey CS, Frazier AL, Gardner JD, Colditz GA. Adolescence and breast carcinoma risk. Cancer 85 (11), 2400–2409 (1999).
   PubMedGoogle Scholar
• Barnes-Josiah D, Potter JD, Sellers TA, Himes JH. Early body size and subsequent weight gain as predictors of breast cancer incidence (Iowa, United States). Cancer Causes Contm16(2), 112–118 (1995).
   Google Scholar
• Van Wiegen JC. Secular growth changes. In: Human growth: a comprehensive treatise, volume 3. Falkner R, Tanner JM (Eds). Plenum Press, London, UK, 307–331 (1986).
   Google Scholar
• Li CI, Malone KE, White E, Daling JR. Age when maximum height is reached as a risk factor for breast cancer among young US women. Epidemiology8(5), 559–565 (1997).
   PubMedGoogle Scholar
• Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAIVIA 286(17), 2143–2151 (2001).
   PubMed Web of Science ®Google Scholar
• •Review of human and animal evidence that alcohol use, even at moderate levels, increases breast cancer risk. Potential mechanisms that may underlie the association, especially increased estrogen and androgen levels, in women who drink, are explained.
   Google Scholar
• Longnecker MP. Alcoholic beverage consumption in relation to risk of breast cancer: meta-analysis and review. Cancer Causes Control 5(1), 73–82 (1994).
   PubMed Web of Science ®Google Scholar
• Hamajima N, Hirose K, Tajima K etal Alcohol, tobacco and breast cancer: collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. BE J. Cancer87 (11), 1234–1245 (2002).
   Google Scholar
• Young TB. A case-control study of breast cancer and alcohol consumption habits. Cancer64(2), 552–558 (1989).
   PubMedGoogle Scholar
• Ginsburg ES. Estrogen, alcohol and breast cancer risk. J. Steroid Biochem. Mol Biol. 69(1–6), 299–306 (1999).
   Google Scholar
• Park SK, Yoo KY, Lee SJ etal Alcohol consumption, glutathione-&transferase M1 and Ti genetic polymorphisms and breast cancer risk. Pharmacogenetics10(4), 301–309 (2000).
   Google Scholar
• Smith-Warner SA, Spiegelman D, Yaun SS et al Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAIVIA 279(7), 535–540 (1998).
   PubMed Web of Science ®Google Scholar
• Baron JA. Smoking and estrogen-related disease. Am. Epidemiol 119(1), 9–22 (1984).
   PubMedGoogle Scholar
• Morabia A, Bernstein M, Heritier S, Khatchatrian N. Relation of breast cancer with passive and active exposure to tobacco smoke. Arn. I Epidemiol 143(9), 918–928 (1996).
   PubMed Web of Science ®Google Scholar
• Welp EA, Weiderpass E, Boffetta P et al Environmental risk factors of breast cancer. Scand.j Work Environ. Health 24(1), 3–7 (1998).
   Google Scholar
• Manjer J, Malina J, Berglund G etal Smoking associated with hormone receptor negative breast cancer. Int. J. Cancer 91(4), 580–584 (2001).
   Google Scholar
• Brunet JS, Ghadirian P, Rebbeck TR etal Effect of smoking on breast cancer in carriers of mutant BRCA 1 or BRCA2genes. I Natl Cancer Inst. 90(10), 761–766 (1998).
   Google Scholar
• Band PR, Le ND, Fang R, Deschamps M. Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet 360(9339), 1044–1049 (2002).
   PubMedGoogle Scholar
• Khuder SA, Mutgi AB, Nugent S. Smoking and breast cancer: a meta-analysis. Rev Environ. Health 16(4), 253–261 (2001).
   Google Scholar
• International Agency for Research on Cancer. Oral contraceptives combined. In: IARC monographs on the evaluation of carrinogenic risks to humans, volume 72. Hormonal contraception and postmenopausal hormonal therapy International Agency for Research on Cancer, Lyon, France, 49–338 (1999).
   Google Scholar
• ••Expert review and evaluation of the riskassociated with the use of contraceptive hormones, showing a small increase in current or recent users, later corroborated by large pooled analyses.
   Google Scholar
• International Agency for Research on Cancer. Hormonal contraceptives, progestogens only. In: IARC monographs on the evaluation of carcinogenic risks to humans, volume 72. Hormonal contraception and postmenopausal hormonal therapy International Agency for Research on Cancer, Lyon, France, 339–397 (1999).
   Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347(9017), 1713–1727 (1996).
   Google Scholar
• International Agency for Research on Cancer. Postmenopausal oestrogen therapy. In: IARC monographs on the evaluation of carrinogenic risks to humans, volume 72. Hormonal contraception and postmenopausal hormonal therapy International Agency for Research on Cancer, Lyon, France, 399–530 (1999). Expert review and evaluation of the risk associated with hormone replacement therapy for menopause (estrogen alone).
   Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084), 1047–1059 (1997).
   Google Scholar
• Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360(9337), 942–944 (2002).
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. Postmenopausal oestrogen-progestogen therapy. In: IARC monographs on the evaluation of carrinogenic risks to humans, volume 72. Hormonal contraception and postmenopausal hormonal therapy International Agency for Research on Cancer, Lyon, France, 531–564 (1999). Expert review and evaluation of the risk associated with hormone replacement therapy for menopause (estrogen plus progestin).
   Google Scholar
• Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int. J. Cancer 72 (5), 758–761 (1997).
   Google Scholar
• Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Conti-0110(4), 253–260 (1999).
   Google Scholar
• Magnusson C, Baron JA, Correia N etal Breast cancer risk following long-term oestrogen- and oestrogen—progestin-replacement therapy. Int. J. Cancer 81(3), 339–344 (1999).
   Google Scholar
• Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. j Nall Cancer Inst. 92(4), 328–332 (2000).
   Google Scholar
• Schairer C, Lubin J, Troisi R et al Menopausal estrogen and estrogen—progestin replacement therapy and breast cancer risk. 161/11A 283(4), 485–491 (2000).
   Google Scholar
• Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J. Epidemiol 152(10), 950–964 (2000).
   Google Scholar
• Stahlberg C, Pedersen AT, Lynge E, Ottesen B. Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet Cynecol Scand 82(4), 335–344 (2003).
   Google Scholar
• Manjer J, Malina J, Berglund G et al Increased incidence of small and well-differentiated breast tumours in postmenopausal women following hormone-replacement therapy. int. J. Cancer92(6), 919–922 (2001).
   Google Scholar
• Bonnier P, Bessenay F, Sasco AJ et al Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int.j Cancer79(3), 278–282 (1998).
   Google Scholar
• Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncol 3(5), 303–311 (2002).
   PubMedGoogle Scholar
• Petitti DB. Hormone replacement therapy for prevention: more evidence, more pessimism. JAMA 288(1), 99–101 (2002).
   PubMedGoogle Scholar
• Grady D, Herrington D, Bittner V etal Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS /AIWA 288(1), 49–57 (2002).
   Google Scholar
• Hulley S, Furberg C, Barrett-Connor E etal Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS /AIWA 288(1), 58–66 (2002).
   Google Scholar
• Rossouw JE, Anderson GL, Prentice RL etal Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAIVIA 288(3), 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE. Estrogen—progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Controll3(9), 847–854 (2002).
   Google Scholar
• Tokunaga M, Land CE, Yamamoto T etal Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950–1980. Radiat. Res. 112(2), 243–272 (1987).
   Google Scholar
• Boice JDJ, Preston D, Davis FG, Monson RR. Frequent chest x-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. Radiat. Res. 125(2), 214–222 (1991).
   PubMed Web of Science ®Google Scholar
• Little MP, Boice JDJ. Comparison of breast cancer incidence in the Massachusetts tuberculosis fluoroscopy cohort and in the Japanese atomic bomb survivors. Radiat. Res. 151(2), 218–224 (1999).
   PubMedGoogle Scholar
• Dosemeci M, Blair A. Occupational cancer mortality among women employed in the telephone industry. I Occup. Environ. Med. 36(11), 1204–1209 (1994).
   Google Scholar
• Coogan PF, Clapp RVV, Newcomb PA etal Occupational exposure to 60-hertz magnetic fields and risk of breast cancer in women. Epidemiology7 (5), 459–464 (1996).
   Google Scholar
• Feychting M, Forssen U, Rutqvist LE, Ahlbom A. Magnetic fields and breast cancer in Swedish adults residing near high-voltage power lines. Epidemiology 9(4), 392–397 (1998).
   PubMedGoogle Scholar
• Cantor IQ, Stewart PA, Brinton LA, Dosemeci M. Occupational exposures and female breast cancer mortality in the United States. J. Occup. Environ. Med. 37(3), 336–348 (1995).
   Google Scholar
• Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CWJ. Occupation and breast cancer mortality in a prospective cohort of US women. Am. J. Epidemiol 148(2), 191–197 (1998).
   Google Scholar
• Petralia SA, Vena JE, Freudenheim JL et al Breast cancer risk and lifetime occupational history: employment in professional and managerial occupations. Occup. Environ. Med. 55(1), 43–48 (1998).
   Google Scholar
• Davis DL, Bradlow HL, Wolff M et al Medical hypothesis: xenoestrogens as preventable causes of breast cancer. Environ. Health. Perspect. 101(5), 372–377 (1993).
   Google Scholar
• Wolff MS, Toniolo PG, Lee EW, Rivera M, Dubin N. Blood levels of organochlorine residues and risk of breast cancer. J. Natl Cancer Inst. 85(8), 648–652 (1993).
   Google Scholar
• Dewailly E, Dodin S, Verreault R etal High organochlorine body burden in women with estrogen receptor-positive breast cancer. j Natl Cancer Inst. 86(3), 232–234 (1994).
   Google Scholar
• Krieger N, Wolff MS, Hiatt RA etal Breast cancer and serum organochlorines: a prospective study among white, black and Asian women. J. Natl Cancer Inst. 86(8), 589–599 (1994).
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Hankinson SE, Laden F et al Plasma organochlorine levels and the risk of breast cancer. N Engl. I Med. 337(18), 1253–1258 (1997).
   Google Scholar
• Lopez-Carrillo L, Blair A, Lopez-Cervantes M etal. Dichlorodiphenyltrichloroethane serum levels and breast cancer risk: a case-control study from Mexico. Cancer Res. 57(17), 3728–3732 (1997).
   PubMed Web of Science ®Google Scholar
• van't Veer P, Lobbezoo IE, Martin-Moreno JM etal DDT (dicophane) and postmenopausal breast cancer in Europe: case-control study. BE Med. J. 315(7100), 81–85 (1997).
   Google Scholar
• Wolff MS, Zeleniuch-Jacquotte A, Dubin N, Toniolo P Risk of breast cancer and organochlorine exposure. Cancer Epidemiol Biomarker s Pmv. 9(3), 271–277 (2000).
   Google Scholar
• Zheng T, Holford TR, Mayne ST etal Risk of female breast cancer associated with serum polychlorinated biphenyls and 1,1-dichloro -2,2' -bis (p-chlorophenyl) ethylene. Cancer Epidemiol Biomarkers Prey. 9(2), 167–174 (2000).
   Google Scholar
• Laden F, Hankinson SE, Wolff MS etal Plasma organochlorine levels and the risk of breast cancer: an extended follow-up in the Nurses' Health Study. Int. J. Cancer 91(4), 568–574 (2001).
   Google Scholar
• Aronson KJ, Miller AB, Wookott CG etal Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk. Cancer Epidemiol Biomarkers Prey. 9(1), 55–63 (2000).
   Google Scholar
• Warner M, Eskenazi B, Mocarelli P etal Serum dioxin concentrations and breast cancer risk in the Seveso Women's Health Study. Environ. Health Perspect. 110(7), 625–628 (2002).
   PubMedGoogle Scholar
• Hoyer AP, Grandjean P, Jorgensen T, Brock JW, Hartvig HB. Organochlorine exposure and risk of breast cancer. Lancet 352(9143), 1816–1820 (1998).
   PubMed Web of Science ®Google Scholar
• Hoyer AP, Jorgensen T, Brock JW, Grandjean P Organochlorine exposure and breast cancer survival. j Clin. Epidendol 53(3), 323–330 (2000).
   Google Scholar
• Demers A, Ayotte P, Brisson J etal Risk and aggressiveness of breast cancer in relation to plasma organochlorine concentrations. Cancer Epidendol Biomarker s Pmv. 9(2), 161–166 (2000).
   Google Scholar
• Laden F, Ishibe N, Hankinson SE etal Polychlorinated biphenyls, cytochrome P450 1A1 and breast cancer risk in the Nurses' Health Study. Cancer Epidemiol Biomarker s Pmv. 11(12), 1560–1565 (2002).
   Google Scholar
• •Recent study demonstrating the need to evaluate risk for pesticides by groups defined on polymorphisms of cytochrome P450, thereby potentially helping to identify high-risk groups.
   Google Scholar
• Safe SH. Xenoestrogens and breast cancer. N. Engl. Med 337(18), 1303–1304 (1997).
   Google Scholar
• Musgrave MA, Aronson KJ, Narod S etal Breast cancer and organochlorines: a marker for susceptibility? Surg. Oncol 7(1-2), 1–4 (1998).
   Google Scholar
• Snedeker SM. Pesticides and breast cancer risk: a review of DDT, DDE and dieldrin. Environ. Health Perspect. 109\(Suppl. 1), 35–47 (2001). iii Charlier C, Albert A, Herman P etal Breast cancer and serum organochlorine residues. Occup. Environ. Med. 60(5), 348–351 (2003).
   Google Scholar
• Brophy JT, Keith MM, Gorey KM etal Occupational histories of cancer patients in a Canadian cancer treatment center and the generated hypothesis regarding breast cancer and farming. Int. J. Occup. Environ. Health 8(4), 346–353 (2002).
   Google Scholar
• Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology 12 (1), 74–77 (2001).
   PubMed Web of Science ®Google Scholar
• Davis S, Mirick DK, Stevens RG. Night shift work, light at night and risk of breast cancer. j Natl Cancer Inst. 93(20), 1557–1562 (2001).
   PubMedGoogle Scholar
• Schemhammer ES, Laden F, Speizer FE etal Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J. Natl Cancer Inst. 93(20), 1563–1568 (2001).
   PubMedGoogle Scholar
• Goldberg MS, Labreche E Occupational risk factors for female breast cancer: a review. Occup. Environ. Med. 53(3), 145–156 (1996).
   Google Scholar
• Dion AS, Girardi AJ, Williams CC, Pomenti AA. Serologic responses to murine mammary tumor virus (MuMTV) in MuMTV-exposed laboratory personnel. Nall Cancer Inst. 76(4), 611–619 (1986).
   Google Scholar
• Stewart TH, Sage RD, Stewart AF, Cameron DW. Breast cancer incidence highest in the range of one species of house mouse, Mus domesticus. BE J. Cancer 82(2), 446–451 (2000).
   Google Scholar
• Glaser SL, Ambinder RF, DiGiuseppe JA, Horn-Ross PL, Hsu JL. Absence of Epstein—Barr virus EBER-1 transcripts in an epidemiologically diverse group of breast cancers. Int. Cancer75(4), 555–558 (1998).
   Google Scholar
• Herrmann K, Niedobitek G. Lack of evidence for an association of Epstein—Barr virus infection with breast carcinoma. Breast Cancer Res. 5(1), R13—R17 (2002).
   Google Scholar
• Easton DF, Narod SA, Ford D, Steel M. The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium. Lancet 344(8924), 761 (1994).
   Google Scholar
• Wooster R, Bignell G, Lancaster J etal Identification of the breast cancer susceptibility gene BRCA2 Nature 378(6559), 789–792 (1995).
   Google Scholar
• Easton DF, Ford D, Bishop DT Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Ain.j Hum. Genet. 56 (1), 265–271 (1995).
   Google Scholar
• Ford D, Easton DF, Stratton M etal Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62(3), 676–689 (1998).
   Google Scholar
• Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. BE J. Cancer 83(10), 1301–1308 (2000).
   Google Scholar
• Warner E, Foulkes W, Goodwin P etal Prevalence and penetrance of BRCA1 and BRCA2gene mutations in unselected Ashkenazi Jewish women with breast cancer. Natl Cancer Inst. 91 (14), 1241–1247 (1999).
   Google Scholar
• Thorlacius S, Sigurdsson S, Bjarnadottir H etal Study of a single BRCA2mutation with high carrier frequency in a small population. Am. J. Hum. Genet. 60 (5), 1079–1084 (1997).
   Google Scholar
• Sobol H, Stoppa-Lyonnet D. Predisposition genetique aux cancers du sein et de l'ovaire: ganaralitas et aspects cliniques. In: Risques hereditaires de cancers du sein et de [ova/jr. Quelle prise en charge ?Les Editions INSERM, Paris, France, 81–104 (1998).
   Google Scholar
• Lichtenstein P, Holm NV, Verkasalo PK et al Environmental and heritable factors in the causation of cancer: analyses of cohort of twins from Sweden, Denmark and Finland. N Engl. J. Med. 343(2), 78–85 (2000).
   Google Scholar
• •Large cohort studies of twins providing estimates of heritable and nonheritable factors in cancer occurrence and indicating a major role of the environment in sporadic tumors.
   Google Scholar
• Risch HA, McLaughlin JR, Cole DE etal Prevalence and penetrance of germline BRCA1 and BRCA2mutations in a population series of 649 women with ovarian cancer. Am. j Hum. Genet. 68(3), 700–710 (2001).
   Google Scholar
• Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nature Genet. 26(4), 411–414 (2000).
   Google Scholar
• Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nature Genet. 31(1), 33–36 (2002).
   Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358 1389–1399 (2001).
   PubMed Web of Science ®Google Scholar
• •Analysis of data from more than 160,000 women indicating that risk of breast cancer increases as number of affected relatives increases. Risk ratios are greater the younger the age at diagnosis.
   Google Scholar
• Narod SA, Goldgar D, Cannon-Albright L et al Risk modifiers in carriers of BRCA1 mutations. Int. J. Cancer 64 (6), 394–398 (1995).
   Google Scholar
• Narod SA, Risch H, Moslehi R etal. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl. J. Med. 339(7), 424–428 (1998).
   Google Scholar
• Jernstrom H, Lerman C, Ghadirian P etal. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2 Lancet 354(9193), 1846–1850 (1999).
   Google Scholar
• Becher H, Schmidt S, Chang-Claude J. Reproductive factors and familial predisposition for breast cancer by age 50 years. A case-control family study for assessing main effects and possible gene-environment interaction. int. I Epic/ern/a 32(1), 38–48 (2003).
   Google Scholar
• Rebbeck TR, Levin AM, Eisen A et al Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl Cancer Inst. 91(17), 1475–1479 (1999).
   Google Scholar
• Narod SA, Dube MP, Klijn J etal. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2mutation carriers. J. Natl Cancer Inst. 94 (23), 1773–1779 (2002).
   Google Scholar
• Siiteri PK. Adipose tissue as a source of hormones. Am. J. Clin. Nutr 45 (Suppl. 1), 277–282 (1987).
   Google Scholar
• Nandi S, Guzman RC, Yang J. Hormones and mammary carcinogenesis in mice, rats and humans: a unifying hypothesis. Proc. Natl Acad. Sci. USA 92(9), 3650–3657 (1995).
   Google Scholar
• Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation and breast cancer risk. Epidemiol Rev 15(1), 17–35 (1993).
   PubMedGoogle Scholar
• Key TJ. Serum oestradiol and breast cancer risk. Endocr. Relat. Cancer6(2), 175–180 (1999).
   Google Scholar
• Bernstein L, Ross RIK. Endogenous hormones and breast cancer risk. Epidemiol Rev 15(1), 48–65 (1993).
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Manson JE etal Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. Natl Cancer Inst. 90 (17), 1292–1299 (1998).
   Google Scholar
• •Case-control study nested within the Nurses' Health Study demonstrating strong evidence for a causal relationship between postmenopausal estrogen levels and breast cancer risk.
   Google Scholar
• la Marca A, Morgante G, Paglia T etal Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil Stern. 72(6), 985–989 (1999).
   Google Scholar
• Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20(4), 535–582 (1999).
   Google Scholar
• Kooks R. Nutrition, hormones and breast cancer: is insulin the missing link? Cancer Causes Control7 (6), 605–625 (1996).
   Google Scholar
• •Explores evidence for chronic hyperinsulinemia as a cause of breast cancer and the extent to which diet and physical activity during childhood determine a hyperandrogenic and higher risk endocrine profile in adulthood by modulating the degree of insulin resistance during adolescence.
   Google Scholar
• Stoll BA. Breast cancer: the obesity connection. BE J. Cancer 69 (5), 799–801 (1994).
   Google Scholar
• Bruning PF, Bonfrer JM, Van Noord PA et al Insulin resistance and breast cancer risk. Int.j Cancer 52 (4), 511–516 (1992) .
   PubMed Web of Science ®Google Scholar
• Del Giudice ME, Fantus IG, Ezzat S etal Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res. Treat. 47(2), 111–120 (1998).
   Google Scholar
• Kaaks R, Lundin E, Manjer J etal Prospective study of IGF-I, IGF-binding proteins and breast cancer risk in northern and southern Sweden. Cancer Causes Contro113(4), 307–316 (2002).
   Google Scholar
• Muti P, Quattrin T, Grant BJ et al Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidendol Biomarkers Bev 11(11), 1361–1368 (2002).
   PubMedGoogle Scholar
• Ursin G, Longnecker MP, Haile RW, Greenland S. A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology6(2), 137–141 (1995).
   PubMed Web of Science ®Google Scholar
• Secreto G, Zumoff B. Abnormal production of androgens in women with breast cancer. AntiCancer Res. 14(5B), 2113–2117 (1994).
   Google Scholar
• Thomas HV, Key TJ, Allen DS etal. A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. BE J. Cancer 75 (7), 1075–1079 (1997).
   Google Scholar
• Helzlsouer KJ, Alberg AJ, Bush TL etal A prospective study of endogenous hormones and breast cancer. Cancer Detect. Prey. 18(2), 79–85 (1994).
   Google Scholar
• Rosenberg CR, Pasternack BS, Shore RE, Koenig KL, Toniolo PG. Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am. J. Epidemiol 140(6), 518–525 (1994).
   Google Scholar
• Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Catrinogenesis 19(1), 1–27 (1998).
   PubMed Web of Science ®Google Scholar
• van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 45(6), 2900–2906 (1985).
   Google Scholar
• Jefcoate CR, Liehr JG, Santen RJ etal Tissue-specific synthesis and oxidative metabolism of estrogens. I Natl Cancer Inst. Monograph 27,95–112 (2000).
   PubMedGoogle Scholar
• Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Ann. Rev Pharmacol Toxicol 36,203–232 (1996).
   PubMed Web of Science ®Google Scholar
• Cavalieri EL, Stack DE, Devanesan PD etal Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Nati Acad. Sc]. USA 94(20), 10937–10942 (1997).
   Google Scholar
• Ball P, Knuppen R. Catecholoestrogens (2-and 4-hydroxyoestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol. Suppl (Copenhagen) 232, 1–127 (1980).
   Google Scholar
• Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther. 57(2–3), 237–257 (1993).
   Google Scholar
• Schneider J, Kinne D, Fracchia A etal Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc. Natl Acad. Sc]. USA 79(9), 3047–3051 (1982).
   Google Scholar
• Fishman J, Schneider J, Hershcope RJ, Bradlow HL. Increased estrogen-16a-hydroxylase activity in women with breast and endometrial cancer. j Steroid Biochem. 20(4B), 1077–1081 (1984).
   Google Scholar
• Bradlow HL, Hershcopf RE, Fishman JF. Oestradiol 16a-hydroxylase: a risk marker for breast cancer. Cancer Surv. 5(3), 573–583 (1986).
   Google Scholar
• Kabat GC, Chang CJ, Sparano JA etal. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarker s Pmv 6(7), 505–509 (1997).
   PubMedGoogle Scholar
• Muti P, Bradlow HL, Micheli A etal Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16a-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 11(6), 635–640 (2000).
   Google Scholar
• Meilahn EN, De Stavola B, Allen DS etal Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br. Cancer78(9), 1250–1255 (1998).
   Google Scholar
• Ursin G, London S, Stanczyk FZ etal Urinary 2-hydroxyestrone/16 a-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. j Natl Cancer Inst. 91(12), 1067–1072 (1999).
   Google Scholar
• Han X, Liehr JG. 8-Hydroxylation of guanine bases in kidney and liver DNA of hamsters treated with estradiol: role of free radicals in estrogen-induced carcinogenesis. Cancer Res. 54(21), 5515–5517 (1994).
   Google Scholar
• Han X, Liehr JG. DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. Carcinogenesis 15(5), 997–1000 (1994).
   PubMedGoogle Scholar
• Khandwala HM, McCutcheon Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21(3), 215–244 (2000).
   PubMed Web of Science ®Google Scholar
• Yu H, Rohan T Role of the insulin-like growth factor family in cancer development and progression.' Nail Cancer Inst. 92(18), 1472–1489 (2000).
   Google Scholar
• Ka:ales R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc. Nutr Soc. 60(1), 91–106 (2001).
   Google Scholar
• Clemmons DR, Underwood LE. Nutritional regulation of IGF-I and IGF binding proteins. Ann. Rev Nutrll, 393–412 (1991).
   Google Scholar
• Straus DS. Nutritional regulation of hormones and growth factors that control mammalian growth. EASE a J. 8(1), 6–12 (1994).
   Google Scholar
• Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 15(1), 80–101 (1994).
   PubMed Web of Science ®Google Scholar
• Cara JE Insulin-like growth factors, insulin-like growth factor binding proteins and ovarian androgen production. Harm. Res. 42(1-2), 49–54 (1994).
   Google Scholar
• Lin T, Haskell J, Vinson N, Terracio L. Direct stimulatory effects of insulin-like growth factor-I on Leydig cell steroidogenesis in primary culture. Biochem. Biophys. Res. Commun. 137(3), 950–956 (1986).
   Google Scholar
• De Mellow JS, Handelsman DJ, Baxter RC. Short-term exposure to insulin-like growth factors stimulates testosterone production by testicular interstitial cells. Acta Endocrinol (Copenhagen) 115 (4), 483–489 (1987).
   PubMedGoogle Scholar
• Plymate SR, Hoop RC, Jones RE, Matej LA. Regulation of sex hormone-binding globulin production by growth factors. Metabolism 39 (9), 967–970 (1990) .
   PubMedGoogle Scholar
• Singh A, Hamilton-Fairley D, Koistinen R etal Effect of insulin-like growth factor-type I (IGF-I) and insulin on the secretion of sex hormone-binding globulin and IGF-I binding protein (IBP-I) by human hepatoma cells. j Endocrinol 124(2), R1—R3 (1990).
   Google Scholar
• Erfurth EM, Hagmar LE, Saaf M, Hall K. Serum levels of insulin-like growth factor I and insulin-like growth factor-binding protein 1 correlate with serum free testosterone and sex hormone binding globulin levels in healthy young and middle-aged men. Clin. Endocrinol 44(6), 659–664 (1996).
   Google Scholar
• Pfeilschifter J, Scheidt-Nave C, Leidig-Bruckner G et al Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50- to 80-year-old men and women. j Clin. Endocrinol Metab. 81(7), 2534–2540 (1996).
   Google Scholar
• Pugeat M, Crave JC, Elmidani M etal Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. Steroid Biochem. Mal Biol. 40(4-6), 841–849 (1991).
   Google Scholar
• Peyrat JP, Bonneterre J, Hecquet B etal Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur Cancer29A(4), 492–497 (1993).
   Google Scholar
• Bruning PF, Van Doom J, Bonfrer JM etal Insulin-like growth factor-binding protein 3 is decreased in early-stage operable premenopausal breast cancer. Int. j Cancer 62(3), 266–270 (1995).
   Google Scholar
• Ng EH, Ji CY, Tan PH etal. Altered serum levels of insulin-like growth factor-binding proteins in breast cancer patients. Ann. Surg. Oncol 5(2), 194–201 (1998).
   Google Scholar
• Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology9(5), 570–573 (1998).
   PubMedGoogle Scholar
• Petridou E, Papadiamantis Y, Markopoulos C et al Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Conti-0111(5), 383–388 (2000).
   Google Scholar
• Hankinson SE, Willett WC, Colditz GA etal Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet351(9113), 1393–1396 (1998).
   PubMed Web of Science ®Google Scholar
• Toniolo P, Bruning PF, Alehmedlehanov A etal Serum insulin-like growth factor-I and breast cancer. Int. j Cancer 88(5), 828–832 (2000).
   PubMed Web of Science ®Google Scholar
• Allen NE, Appleby PN, Davey GK, Key TJ. Hormones and diet: low insulin-like growth factor-I but normal bioavailable androgens in vegan men. BE j Cancer 83(1), 95–97 (2000).
   Google Scholar
• Hall K, Hilding A, Thoren M. Determinants of circulating insulin-like growth factor-I. j Endocrinol Invest. 22 (Suppl. 5), 48–57 (1999).
   Google Scholar
• Hong Y, Brismar K, Hall K, Pedersen NL, de Faire U. Associations between insulin- like growth factor-IIGF-bindingprotein-1, insulin and other metabolic measures after controlling for genetic influences: results from middle-aged and elderly monozygotic twins. j Endocrinol 153(2), 251–257 (1997).
   Google Scholar
• Harrela M, Koistinen H, Kaprio J et al Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1 and IGFBP-3.j Clin. Invest. 98 (11), 2612–2615 (1996).
   Google Scholar
• Verhaeghe J, Loos R, Vlietinck R etal C-peptide, insulin-like growth factors I and II and insulin-like growth factor binding protein-1 in cord serum of twins: genetic versus environmental regulation. Am. Obstet. Gynecol 175(5), 1180–1188 (1996).
   Google Scholar
• Lopez-Bermejo A, Buckway CK, Rosenfeld RG. Genetic defects of the growth hormone-insulin-like growth factor axis. Trends Endocrinol. Metab. 11(2), 39–49 (2000).
   Google Scholar
• Jernstrom H, Deal C, Wilkin F etal Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Pmv. 10(4), 377–384 (2001).
   Google Scholar
• Cogan JD, Phillips JA III. Growth disorders caused by genetic defects in the growth hormone pathway. Adv. Perliatr 45, 337–361 (1998).
   PubMedGoogle Scholar
• Rasmussen SK, Lautier C, Hansen L etal Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to Type 2 diabetes mellitus. j Clin. Endocrinol. Metab. 85(4), 1606–1610 (2000).
   Google Scholar
• Sun G, Chagnon M, Bouchard C. A common polymorphism in the human insulin-like growth factor binding protein 3 gene. Ma Cell Probes 14(1), 55–56 (2000).
   Google Scholar
• Sasi R, Puebla L, Khare S, Patel YC. Polymorphism in the 5- flanking region of the human somatostatin receptor subtype 5. Gene 214(1–2), 45–49 (1998).
   Google Scholar
• Giordano M, Marchetti C, Chiorboli E, Bona G, Momigliano RP. Evidence for gene conversion in the generation of extensive polymorphism in the promoter of the growth hormone gene. Hum. Genet. 100(2), 249–255 (1997).
   Google Scholar
• Chujo S, Kaji H, Takahashi Y etal No correlation of growth hormone receptor gene mutation P561T with body height. Eur Endocrinol. 134(5), 560–562 (1996).
   Google Scholar
• Yamada Y, Stoffel M, Espinosa R III etal Human somatostatin receptor genes: localization to human chromosomes 14,17 and 22 and identification of simple tandem repeat polymorphisms. Genomics 15(2), 449–452 (1993).
   Google Scholar
• Innes KE, Byers TE. Pre-eclampsia and breast cancer risk. Epidemiology10 (6), 722–732 (1999).
   PubMedGoogle Scholar
• Michels KB, Trichopoulos D, Robins JM etal Birthweight as a risk factor for breast cancer. Lancet 348 (9041), 1542–1546 (1996).
   PubMedGoogle Scholar
• Andersson SW, Bengtsson C, Hallberg L etal Cancer risk in Swedish women: the relation to size at birth. BE j Cancer 84(9), 1193–1198 (2001).
   Google Scholar
• Cerhan JR, Kushi LH, Olson JE etal. Twinship and risk of postmenopausal breast cancer. Natl Cancer Inst. 92 (3), 261–265 (2000).
   Google Scholar
• •Large cohort study indicating the importance of in utero environment on breast cancer risk with a higher risk for twins as compared with singletons
   Google Scholar
• Lipworth L, Hsieh CC, Wide L etal Maternal pregnancy hormone levels in an area with a high incidence (Boston, USA) and in an area with a low incidence (Shanghai, China) of breast cancer. BE Cancer79(1), 7–12 (1999).
   Google Scholar
• Shu XO, Jin F, Dai Q etal. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarker s Prey. 10(5), 483–488 (2001).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL etal Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. .1. Natl Cancer Inst. 90 (18), 1371–1388 (1998).
   Google Scholar
• Powles T, Eeles R, Ashley S etal Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352(9122), 98–101 (1998).
   PubMed Web of Science ®Google Scholar
• Veronesi U, Maisonneuve P, Costa A etal Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352 (9122), 93–97 (1998).
   PubMed Web of Science ®Google Scholar
• IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360(9336), 817–824 (2002).
   PubMedGoogle Scholar
• Cuzick J, Powles T, Veronesi U etal. Overview of the main outcomes in breast cancer prevention trials. Lancet 361(9354), 296–300 (2003).
   PubMed Web of Science ®Google Scholar
• Sasco AJ, Besson H, Bianchini E Oil en est-on en chimioprévention? Oncologie 4, 488–492 (2002).
   Google Scholar